display ongoing
results: demonstrated suggested inconclusive safety concern ongoing study
metastatic/adv melanoma (mML)
mML - L1 - all population
immune chekpoint inhibitors
anti-CTLA-4
tremelimumab A3671009
anti-PD-(L)1
nivolumab based treatment
nivolumab alone CheckMate 067 ...
nivolumab followed by ipilimumab CheckMate 064
Immune checkpoint association
nivolumab plus ipilimumab CheckMate 067 ... CheckMate 069 ... CheckMate 067 ...
relatlimab plus nivolumab RELATIVITY-047

Study type:

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons